Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury.

Hook GR, Yu J, Sipes N, Pierschbacher MD, Hook V, Kindy MS.

J Neurotrauma. 2014 Mar 1;31(5):515-29. doi: 10.1089/neu.2013.2944. Epub 2014 Feb 6.

2.

Glioma cell integrin expression and their interactions with integrin antagonists: Research Article.

Mattern RH, Read SB, Pierschbacher MD, Sze CI, Eliceiri BP, Kruse CA.

Cancer Ther. 2005;3A:325-340.

3.

Incorporation of thioether building blocks into an alphavbeta3-specific RGD peptide: synthesis and biological activity.

Kelleman A, Mattern RH, Pierschbacher MD, Goodman M.

Biopolymers. 2003;71(6):686-95.

PMID:
14991678
4.

Studies of the receptor-bound conformation of alphaIIbbeta3 antagonists by 15N-edited NMR spectroscopy.

Locardi E, Mattern RH, Malaney TI, Minasyan R, Pierschbacher MD, Taulane JP, Goodman M.

Biopolymers. 2002;66(5):326-38.

PMID:
12539261
5.

Incorporation of (2S,3S) and (2S,3R) beta-methyl aspartic acid into RGD-containing peptides.

Schabbert S, Pierschbacher MD, Mattern RH, Goodman M.

Bioorg Med Chem. 2002 Oct;10(10):3331-7.

PMID:
12150880
6.

Receptor-bound conformation of an alpha(5)beta(1) integrin antagonist by (15)N-edited 2D transferred nuclear overhauser effects.

Zhang L, Mattern RH, Malaney TI, Pierschbacher MD, Goodman M.

J Am Chem Soc. 2002 Mar 27;124(12):2862-3.

PMID:
11902863
7.

Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia.

Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, del Zoppo GJ.

Stroke. 2000 Jun;31(6):1402-09; discussion 1409-10.

PMID:
10835463
8.

Enhancement of cell interactions with collagen/glycosaminoglycan matrices by RGD derivatization.

Grzesiak JJ, Pierschbacher MD, Amodeo MF, Malaney TI, Glass JR.

Biomaterials. 1997 Dec;18(24):1625-32.

PMID:
9613810
9.

Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis.

Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD.

Biochem Pharmacol. 1997 Dec 1;54(11):1205-16.

PMID:
9416971
10.
11.

Effects of an arginine-glycine-aspartic acid peptide-containing artificial matrix on epithelial migration in vitro and experimental second-degree burn wound healing in vivo.

Mertz PM, Davis SC, Franzen L, Uchima FD, Pickett MP, Pierschbacher MD, Polarek JW.

J Burn Care Rehabil. 1996 May-Jun;17(3):199-206.

PMID:
8736364
14.

Concept and progress in the development of RGD-containing peptide pharmaceuticals.

Craig WS, Cheng S, Mullen DG, Blevitt J, Pierschbacher MD.

Biopolymers. 1995;37(2):157-75. Review. Erratum in: Biopolymers 1995;37(5):363.

PMID:
7534489
15.

Manipulation of cellular interactions with biomaterials toward a therapeutic outcome: a perspective.

Pierschbacher MD, Polarek JW, Craig WS, Tschopp JF, Sipes NJ, Harper JR.

J Cell Biochem. 1994 Oct;56(2):150-4. Review.

PMID:
7829572
16.

Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time.

Mazur C, Tschopp JF, Faliakou EC, Gould KE, Diehl JT, Pierschbacher MD, Connolly RJ.

J Lab Clin Med. 1994 Oct;124(4):589-99.

PMID:
7523555
17.

Inhibition of thrombosis by a selective fibrinogen receptor antagonist without effect on bleeding time.

Tschopp JF, Mazur C, Gould K, Connolly R, Pierschbacher MD.

Thromb Haemost. 1994 Jul;72(1):119-24.

PMID:
7974359
18.

Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.

Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D, Pierschbacher MD.

J Med Chem. 1994 Jan 7;37(1):1-8.

PMID:
7507165
19.

Therapeutic application of matrix biology.

Tschopp JF, Craig WS, Tolley J, Blevitt J, Mazur C, Pierschbacher MD.

Methods Enzymol. 1994;245:556-69. No abstract available.

PMID:
7760751
20.

Role of transforming growth factor beta and decorin in controlling fibrosis.

Harper JR, Spiro RC, Gaarde WA, Tamura RN, Pierschbacher MD, Noble NA, Stecker KK, Border WA.

Methods Enzymol. 1994;245:241-54. No abstract available.

PMID:
7760736
21.

Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time.

Tschopp JF, Driscoll EM, Mu DX, Black SC, Pierschbacher MD, Lucchesi BR.

Coron Artery Dis. 1993 Sep;4(9):809-17.

PMID:
8287215
22.

A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin.

Tomasini-Johansson BR, Ruoslahti E, Pierschbacher MD.

Matrix. 1993 May;13(3):203-14.

PMID:
7686999
23.

A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin.

Vogel BE, Lee SJ, Hildebrand A, Craig W, Pierschbacher MD, Wong-Staal F, Ruoslahti E.

J Cell Biol. 1993 Apr;121(2):461-8.

24.

Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Yu, Pierschbacher MD, Ruoslahti E.

Nature. 1992 Nov 26;360(6402):361-4.

PMID:
1280332
25.

Regulation of alpha 2 beta 1-mediated fibroblast migration on type I collagen by shifts in the concentrations of extracellular Mg2+ and Ca2+.

Grzesiak JJ, Davis GE, Kirchhofer D, Pierschbacher MD.

J Cell Biol. 1992 Jun;117(5):1109-17. Erratum in: J Cell Biol 1992 Jul;118(1):219.

26.

Calcium as a potential physiological regulator of integrin-mediated cell adhesion.

Kirchhofer D, Grzesiak J, Pierschbacher MD.

J Biol Chem. 1991 Mar 5;266(7):4471-7.

27.

Comparison of two phosphoproteins in chicken bone and their similarities to the mammalian bone proteins, osteopontin and bone sialoprotein II.

Gotoh Y, Pierschbacher MD, Grzesiak JJ, Gerstenfeld L, Glimcher MJ.

Biochem Biophys Res Commun. 1990 Nov 30;173(1):471-9.

PMID:
1701638
28.

Cation-dependent changes in the binding specificity of the platelet receptor GPIIb/IIIa.

Kirchhofer D, Gailit J, Ruoslahti E, Grzesiak J, Pierschbacher MD.

J Biol Chem. 1990 Oct 25;265(30):18525-30.

29.

Alpha 2 beta 1 integrins from different cell types show different binding specificities.

Kirchhofer D, Languino LR, Ruoslahti E, Pierschbacher MD.

J Biol Chem. 1990 Jan 15;265(2):615-8.

30.
31.

Preferential expression of fibronectin receptors on immature thymocytes.

Cardarelli PM, Crispe IN, Pierschbacher MD.

J Cell Biol. 1988 Jun;106(6):2183-90.

32.

Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides.

Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E.

J Cell Biol. 1988 Mar;106(3):925-30. Erratum in: J Cell Biol 1989 Jun;108(6):following 2546.

33.

An adhesion variant of the MG-63 osteosarcoma cell line displays an osteoblast-like phenotype.

Pierschbacher MD, Dedhar S, Ruoslahti E, Argraves S, Suzuki S.

Ciba Found Symp. 1988;136:131-41. Review.

PMID:
3068006
34.

Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion.

Pierschbacher MD, Ruoslahti E.

J Biol Chem. 1987 Dec 25;262(36):17294-8.

35.

New perspectives in cell adhesion: RGD and integrins.

Ruoslahti E, Pierschbacher MD.

Science. 1987 Oct 23;238(4826):491-7. Review.

PMID:
2821619
36.

Amino acid sequence of the vitronectin receptor alpha subunit and comparative expression of adhesion receptor mRNAs.

Suzuki S, Argraves WS, Arai H, Languino LR, Pierschbacher MD, Ruoslahti E.

J Biol Chem. 1987 Oct 15;262(29):14080-5.

37.

Amino acid sequence of the human fibronectin receptor.

Argraves WS, Suzuki S, Arai H, Thompson K, Pierschbacher MD, Ruoslahti E.

J Cell Biol. 1987 Sep;105(3):1183-90.

38.

Human osteosarcoma cells resistant to detachment by an Arg-Gly-Asp-containing peptide overproduce the fibronectin receptor.

Dedhar S, Argraves WS, Suzuki S, Ruoslahti E, Pierschbacher MD.

J Cell Biol. 1987 Sep;105(3):1175-82.

39.
40.

Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets.

Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH.

Blood. 1987 Jul;70(1):110-5.

PMID:
3036276
41.

Identification of fibronectin receptors on T lymphocytes.

Cardarelli PM, Pierschbacher MD.

J Cell Biol. 1987 Jul;105(1):499-506.

42.

A cell surface receptor complex for collagen type I recognizes the Arg-Gly-Asp sequence.

Dedhar S, Ruoslahti E, Pierschbacher MD.

J Cell Biol. 1987 Mar;104(3):585-93.

43.

Arginine-glycine-aspartic acid adhesion receptors.

Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Ruoslahti E.

Methods Enzymol. 1987;144:475-89. No abstract available.

PMID:
2442581
44.

Purification and characterization of vitronectin.

Ruoslahti E, Suzuki S, Hayman EG, Ill CR, Pierschbacher MD.

Methods Enzymol. 1987;144:430-7. No abstract available.

PMID:
2442580
45.

cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors.

Suzuki S, Argraves WS, Pytela R, Arai H, Krusius T, Pierschbacher MD, Ruoslahti E.

Proc Natl Acad Sci U S A. 1986 Nov;83(22):8614-8.

46.

cDNA sequences from the alpha subunit of the fibronectin receptor predict a transmembrane domain and a short cytoplasmic peptide.

Argraves WS, Pytela R, Suzuki S, Millán JL, Pierschbacher MD, Ruoslahti E.

J Biol Chem. 1986 Oct 5;261(28):12922-4.

47.
48.

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors.

Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E.

Science. 1986 Mar 28;231(4745):1559-62.

PMID:
2420006
49.
50.

Arg-Gly-Asp: a versatile cell recognition signal.

Ruoslahti E, Pierschbacher MD.

Cell. 1986 Feb 28;44(4):517-8. No abstract available.

PMID:
2418980

Supplemental Content

Loading ...
Support Center